eric
06-03-2008, 05:36 PM
http://www.medicalnewstoday.com/articles/109561.php
Early Data Presented At ASCO Show Potential Of RAD001 To Enhance Efficacy Of, And Overcome Resistance To, Breast Cancer Treatments
initial results from two Phase I trials in which RAD001 was combined with trastuzumab (Herceptin (http://www.medilexicon.com/drugs/herceptin.php)®) and chemotherapy agents suggest that the addition of RAD001 overcame resistance to trastuzumab. The combination appears highly active, achieving complete responses in a few patients and partial responses or stable disease in a majority of patients.
Early Data Presented At ASCO Show Potential Of RAD001 To Enhance Efficacy Of, And Overcome Resistance To, Breast Cancer Treatments
initial results from two Phase I trials in which RAD001 was combined with trastuzumab (Herceptin (http://www.medilexicon.com/drugs/herceptin.php)®) and chemotherapy agents suggest that the addition of RAD001 overcame resistance to trastuzumab. The combination appears highly active, achieving complete responses in a few patients and partial responses or stable disease in a majority of patients.